![Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders | Neurology Genetics Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders | Neurology Genetics](https://www.neurology.org/cms/10.1212/NXG.0000000000200071/asset/5a9a81d6-0d10-4e73-8105-eb3f0ad9514f/assets/images/large/nxg.0000000000200071t1.jpg)
Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders | Neurology Genetics
![Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 | Circulation Research Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 | Circulation Research](https://www.ahajournals.org/cms/asset/d7e6b14d-fe32-4ace-bdcf-eca9d3c64902/circresaha.120.317703.fig07.jpg)
Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 | Circulation Research
![Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders | Neurology Genetics Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders | Neurology Genetics](https://www.neurology.org/cms/10.1212/NXG.0000000000200071/asset/c878e8be-61dc-45a0-904e-fd2393530c56/assets/images/large/nxg.0000000000200071tu1.jpg)
Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders | Neurology Genetics
![Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years | Pharmacological Reviews Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years | Pharmacological Reviews](https://pharmrev.aspetjournals.org/content/pharmrev/75/5/885/F8.large.jpg)
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years | Pharmacological Reviews
![Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years | Pharmacological Reviews Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years | Pharmacological Reviews](https://pharmrev.aspetjournals.org/content/pharmrev/75/5/885/F1.large.jpg)